Since the outbreak of covid-19, the team of Associate Professor Liang Chengyuan from the Department of pharmacy of our hospital has been in the European Journal of Medicinal Chemistry (3 articles), Biomedcine & Pharmacotherapy (1 article), Phytomedicine Plus (1) published a series of new coronavirus drug treatment research review, summarized the current recommendations for the main drug treatment of covid-19, to provide guidance for the drug research and clinical use of covid-19.
1、 Lianhua Qingwen capsule
In the prevention and control of new crown pneumonia and the treatment of patients, the extensive application of traditional Chinese medicine and the remarkable clinical curative effect achieved. A number of traditional Chinese medicine, represented by Lianhua Qingwen capsule, are speeding up the "going out to sea", making the value of traditional Chinese medicine further affirmed by the international community. In April 2020, Lianhua Qingwen capsules and granules were approved by CFDA for the treatment of common and mild new crown pneumonia patients.
Figure 1: prescription of Lianhua Qingwen capsule
"Medical chemistry insights into Forsythia honeysuckle (Lianhua Qingwen) capsules: a Chinese herb medicine repeated for covid-19 pandemics" is a comprehensive review of Lianhua Qingwen capsule from the perspective of pharmacochemistry from the perspective of pharmacochemistry, including formula, preparation process, quality standard, bioactive components and their mechanism of action  。 Through literature studies, phillyrin inhibits JAK / STAT pathway to regulate IL-6 and other inflammatory factors, and then controls inflammatory factor storm to achieve anti-inflammatory effect in the treatment of new crown pneumonia. The antiviral mechanism of Lianhua Qingwen capsule may depend on the competitive binding of quercetin and naringenin to ACE2, thus blocking the binding of virus S protein with ACE2, and further blocking the entry of coronavirus into the body. At the same time, eight active components such as rutin could inhibit the 3CL of coronavirus pro It can effectively block the process of RNA replication and transcription, thus blocking virus replication.
Figure 2: schematic diagram of mechanism of Lianhua Qingwen capsule in the treatment of covid-19
2、 Small molecule drugs targeting key viral proteins
《An update review of emerging small-molecule therapeutic options for COVID-19》、《The development of Coronavirus 3C-Like protease (3CL pro ）A variety of small molecule drug treatment strategies related to covid-19 treatment were systematically introduced in three articles, inhibitors from 2010 to 2020 and RNA dependent RNA polymerase (RdRp) inhibitors: the current landscape and recycling for the coved-19 peripheral  Including RNA dependent RNA polymerase (RdRp)  And 3C - like protease (3CL) pro ）  In addition, the mechanism of action and the structure-activity relationship were discussed. The author team also proposed and explained 3CL pro The research and development idea of reversible covalent protacs combines the "occupation driven" of small molecule inhibitors with the "event driven" of protacs to form multi round pairs of 3CL at low dose pro The inhibition and degradation of 3CL in the invaded cells were eliminated pro The accumulation of 3CL was blocked completely pro It can inhibit the assembly and replication of coronavirus in cells.
Figure 3 3CL pro Design of reversible covalent protacs anti coronavirus drugs
3、 Redseway（ Remdesivir ）
Figure 4 Inhibition of replication of sars-cov2 by radcivir
Remdesivir is a monophosphamide prodrug of adenosine analogues. It targets the virus RdRp, resulting in the termination of RNA chain synthesis and inhibition of virus replication. In the early stage of the outbreak of covid-19, radcivir, a broad-spectrum antiviral drug, may have great prospects in the treatment of new coronal pneumonia. A promising antiviral candidate drug for the covid-19 pandemics: a mini review of remdesivir systematically reviewed the related pharmaceutical research of redcivir, including its research and development progress, intellectual property rights, and anti coronavirus mechanism, This article introduces the latest progress of radcivir in the treatment of covid-19  。
Links to related papers:
 Liang Chengyuan*; Hui Nan; Liu Yuzhi et al.; Medicinal Chemistry Insights into Forsythia Honeysuckle (Lianhuaqingwen) Capsules：A Chinese Herbal Medicine Repurposed for COVID-19 Pandemic, Phytomedicine Plus , 2021.100027. http://www.sciencedirect.com/science/article/pii/S2667031321000099
 Dengke Tian; Yuzhi Liu; Chengyuan Liang *et al.; An update review of emerging small-molecule therapeutic options for COVID-19, Biomedicine & Pharmacotherapy , 2021, 137: 111313. http://www.sciencedirect.com/science/article/pii/S0753332221000986
 Tian Lei; Qiang Taotao; Liang Chengyuan* et al.; RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic, European Journal of Medicinal Chemistry , 2021, 213: 113201. http://www.sciencedirect.com/science/article/pii/S0223523421000507
 Liu Yuzhi; Liang Chengyuan*; Xin Liang et al.; The development of Coronavirus 3C-Like protease (3CL pro ) inhibitors from 2010 to 2020, European Journal of Medicinal Chemistry , 2020, 206:112711. http://www.sciencedirect.com/science/article/pii/S0223523420306838
 Liang Chengyuan*; Tian Lei; Liu Yuzhi et al.; A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir, European Journal of Medicinal Chemistry , 2020.112527. http://www.sciencedirect.com/science/article/pii/S0223523420304992
A brief introduction to the author
Liang Chengyuan, male, associate professor, Department of pharmacy, School of food and Bioengineering, Shaanxi University of science and technology. Research directions: development of small molecule kinase inhibitors, improvement of traditional Chinese medicine technology and quality standards, research and development of multi drug resistant bacteria antibiotics. He has presided over one National Natural Science Foundation, four provincial and ministerial level projects, eight Department and bureau level projects, more than 30 horizontal projects and achievements transformation of enterprises, and more than 20 invention patents authorized by the United States and Japan, and 26 Chinese invention patents. stay European Journal of Medicinal Chemistry , Food & Function , Journal of Functional Foods, Biomedicine & Pharmacotherapy More than 50 scientific papers have been published in Chinese Journal of antibiotics and other journals.